Patient ID,PDO,Drug,IC50(µM),LOG10 IC50(µM),Response category,Emax(% maximum inhibition)
108_T,108_T_XEN_CELL,sorafenib,11.5937,1.0642,Resistant,99.00
108_T,108_T_XEN_CELL,linifanib,10.9098,1.0378,Resistant,77.74
108_T,108_T_XEN_CELL,regorafenib,9.1760,0.9627,Resistant,93.80
108_T,108_T_XEN_CELL,sunitinib,8.2691,0.9175,Resistant,99.30
108_T,108_T_XEN_CELL,5-FU,>60.0000,1.7782,Resistant,44.00
108_T,108_T_XEN_CELL,oxaliplatin,3.8507,0.5855,Minor response,55.20
108_T,108_T_XEN_CELL,nintedanib,3.0562,0.4852,Minor response,98.68
108_T,108_T_XEN_CELL,vandetanib,1.3605,0.1337,Minor response,100.90
108_T,108_T_XEN_CELL,BI 860585,0.8373,-0.0771,Minor response,99.30
108_T,108_T_XEN_CELL,gefitinib,0.7327,-0.1351,Minor response,80.20
108_T,108_T_XEN_CELL,selumetinib,0.0932,-1.0306,Moderate response,83.29
108_T,108_T_XEN_CELL,staurosporine,0.0416,-1.3809,Moderate response,101.14
108_T,108_T_XEN_CELL,AZD8931,0.0327,-1.4855,Strong response,89.90
108_T,108_T_XEN_CELL,afatinib,0.0251,-1.6003,Strong response,100.10
114_T,114_T_XEN_CELL,AZD8931,60.0000,1.7782,Resistant,57.10
114_T,114_T_XEN_CELL,gefitinib,60.0000,1.7782,Resistant,61.70
114_T,114_T_XEN_CELL,linifanib,60.0000,1.7782,Resistant,85.54
114_T,114_T_XEN_CELL,regorafenib,60.0000,1.7782,Resistant,62.60
114_T,114_T_XEN_CELL,sorafenib,60.0000,1.7782,Resistant,71.30
114_T,114_T_XEN_CELL,vandetanib,60.0000,1.7782,Resistant,98.20
114_T,114_T_XEN_CELL,sunitinib,28.5061,1.4549,Resistant,99.70
114_T,114_T_XEN_CELL,nintedanib,18.0403,1.2562,Resistant,78.69
114_T,114_T_XEN_CELL,afatinib,17.7482,1.2492,Resistant,99.80
114_T,114_T_XEN_CELL,BI 860585,10.1336,1.0058,Resistant,96.70
114_T,114_T_XEN_CELL,5-FU,>60.0000,1.7782,Resistant,19.40
114_T,114_T_XEN_CELL,oxaliplatin,>60.0000,1.7782,Resistant,24.30
114_T,114_T_XEN_CELL,selumetinib,2.1690,0.3363,Minor response,95.81
114_T,114_T_XEN_CELL,staurosporine,0.2775,-0.5567,Moderate response,97.21
116_T,116_T_XEN_CELL,sorafenib,20.5653,1.3131,Resistant,86.00
116_T,116_T_XEN_CELL,regorafenib,10.8427,1.0351,Resistant,89.00
116_T,116_T_XEN_CELL,sunitinib,7.2437,0.8600,Resistant,97.80
116_T,116_T_XEN_CELL,linifanib,6.5276,0.8148,Resistant,75.34
116_T,116_T_XEN_CELL,5-FU,>60.0000,1.7782,Resistant,35.60
116_T,116_T_XEN_CELL,oxaliplatin,>60.0000,1.7782,Resistant,38.70
116_T,116_T_XEN_CELL,nintedanib,3.7354,0.5723,Minor response,97.77
116_T,116_T_XEN_CELL,gefitinib,2.3519,0.3714,Minor response,82.30
116_T,116_T_XEN_CELL,vandetanib,1.7420,0.2410,Minor response,100.60
116_T,116_T_XEN_CELL,selumetinib,1.6475,0.2168,Minor response,89.82
116_T,116_T_XEN_CELL,BI 860585,0.3733,-0.4279,Moderate response,97.00
116_T,116_T_XEN_CELL,AZD8931,0.0664,-1.1778,Moderate response,62.60
116_T,116_T_XEN_CELL,staurosporine,0.0281,-1.5513,Strong response,97.77
116_T,116_T_XEN_CELL,afatinib,0.0142,-1.8477,Strong response,55.80
151_METa,151_MET_CELL1,AZD8931,60.0000,1.7782,Resistant,63.70
151_METa,151_MET_CELL1,sorafenib,19.6655,1.2937,Resistant,95.00
151_METa,151_MET_CELL1,afatinib,10.9755,1.0404,Resistant,98.80
151_METa,151_MET_CELL1,vandetanib,9.4509,0.9755,Resistant,99.00
151_METa,151_MET_CELL1,regorafenib,7.9872,0.9024,Resistant,96.30
151_METa,151_MET_CELL1,5-FU,>60.0000,1.7782,Resistant,43.50
151_METa,151_MET_CELL1,gefitinib,>60.0000,1.7782,Resistant,33.60
151_METa,151_MET_CELL1,oxaliplatin,>60.0000,1.7782,Resistant,24.00
151_METa,151_MET_CELL1,nintedanib,4.7090,0.6729,Minor response,98.70
151_METa,151_MET_CELL1,sunitinib,2.8715,0.4581,Minor response,98.70
151_METa,151_MET_CELL1,BI 860585,0.6493,-0.1876,Minor response,61.70
151_METa,151_MET_CELL1,linifanib,0.3925,-0.4062,Moderate response,86.45
151_METa,151_MET_CELL1,selumetinib,0.1358,-0.8671,Moderate response,56.47
151_METa,151_MET_CELL1,staurosporine,0.0186,-1.7305,Strong response,99.45
152_T,152_T_CELL,afatinib,0.0634,-1.1979,Moderate response,49.50
152_T,152_T_CELL,gefitinib,60.0000,1.7782,Resistant,64.30
152_T,152_T_CELL,linifanib,60.0000,1.7782,Resistant,81.64
152_T,152_T_CELL,regorafenib,60.0000,1.7782,Resistant,86.70
152_T,152_T_CELL,sorafenib,60.0000,1.7782,Resistant,75.50
152_T,152_T_CELL,sunitinib,60.0000,1.7782,Resistant,99.20
152_T,152_T_CELL,vandetanib,17.5848,1.2451,Resistant,78.70
152_T,152_T_CELL,selumetinib,10.5670,1.0240,Resistant,95.47
152_T,152_T_CELL,nintedanib,6.4200,0.8075,Resistant,98.19
152_T,152_T_CELL,5-FU,>60.0000,1.7782,Resistant,27.10
152_T,152_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,33.60
152_T,152_T_CELL,BI 860585,4.2609,0.6295,Minor response,99.10
152_T,152_T_CELL,AZD8931,3.0893,0.4899,Minor response,93.70
152_T,152_T_CELL,staurosporine,0.0736,-1.1331,Moderate response,100.01
155_T,155_T_XEN_CELL,sorafenib,11.2622,1.0516,Resistant,90.00
155_T,155_T_XEN_CELL,linifanib,10.9659,1.0400,Resistant,105.55
155_T,155_T_XEN_CELL,sunitinib,7.8023,0.8922,Resistant,117.40
155_T,155_T_XEN_CELL,AZD8931,5.6477,0.7519,Resistant,87.70
155_T,155_T_XEN_CELL,vandetanib,5.5700,0.7459,Resistant,113.20
155_T,155_T_XEN_CELL,5-FU,>60.0000,1.7782,Resistant,40.80
155_T,155_T_XEN_CELL,oxaliplatin,>60.0000,1.7782,Resistant,31.20
155_T,155_T_XEN_CELL,regorafenib,4.3466,0.6381,Minor response,76.60
155_T,155_T_XEN_CELL,gefitinib,2.5680,0.4096,Minor response,91.30
155_T,155_T_XEN_CELL,afatinib,1.7544,0.2441,Minor response,117.00
155_T,155_T_XEN_CELL,nintedanib,1.5219,0.1824,Minor response,114.68
155_T,155_T_XEN_CELL,BI 860585,1.0110,0.0048,Minor response,105.70
155_T,155_T_XEN_CELL,selumetinib,0.3546,-0.4503,Moderate response,101.07
155_T,155_T_XEN_CELL,staurosporine,0.0922,-1.0353,Moderate response,93.08
155_T,155_T_XEN_CELL,irinotecan,14.2076,1.1525,Resistant,73.40
159_T,159_T_CELL,gefitinib,12.7291,1.1048,Resistant,91.50
159_T,159_T_CELL,sorafenib,8.8150,0.9452,Resistant,61.80
159_T,159_T_CELL,regorafenib,7.0722,0.8496,Resistant,74.00
159_T,159_T_CELL,5-FU,>60.0000,1.7782,Resistant,19.90
159_T,159_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,16.20
159_T,159_T_CELL,vandetanib,3.8660,0.5873,Minor response,91.70
159_T,159_T_CELL,afatinib,3.4971,0.5437,Minor response,100.10
159_T,159_T_CELL,nintedanib,2.9901,0.4757,Minor response,99.74
159_T,159_T_CELL,sunitinib,2.0886,0.3199,Minor response,94.20
159_T,159_T_CELL,selumetinib,0.5818,-0.2352,Minor response,59.28
159_T,159_T_CELL,AZD8931,0.3958,-0.4025,Moderate response,85.60
159_T,159_T_CELL,BI 860585,0.0669,-1.1743,Moderate response,57.00
159_T,159_T_CELL,linifanib,0.0341,-1.4667,Strong response,54.88
159_T,159_T_CELL,staurosporine,0.0179,-1.7462,Strong response,96.77
159_T,159_T_CELL,irinotecan,60.0000,1.7782,Resistant,16.80
161_T,161_T_XEN_CELL,sunitinib,60.0000,1.7782,Resistant,100.60
161_T,161_T_XEN_CELL,AZD8931,43.4151,1.6376,Resistant,69.00
161_T,161_T_XEN_CELL,linifanib,36.2038,1.5588,Resistant,74.24
161_T,161_T_XEN_CELL,gefitinib,30.3323,1.4819,Resistant,99.50
161_T,161_T_XEN_CELL,BI 860585,30.1616,1.4795,Resistant,90.70
161_T,161_T_XEN_CELL,nintedanib,28.1217,1.4490,Resistant,96.83
161_T,161_T_XEN_CELL,vandetanib,27.9638,1.4466,Resistant,87.20
161_T,161_T_XEN_CELL,afatinib,17.4685,1.2423,Resistant,100.80
161_T,161_T_XEN_CELL,selumetinib,11.8316,1.0730,Resistant,82.53
161_T,161_T_XEN_CELL,sorafenib,8.3529,0.9218,Resistant,98.90
161_T,161_T_XEN_CELL,oxaliplatin,>60.0000,1.7782,Resistant,26.50
161_T,161_T_XEN_CELL,regorafenib,3.5456,0.5497,Minor response,95.10
161_T,161_T_XEN_CELL,5-FU,0.6093,-0.2152,Minor response,57.00
161_T,161_T_XEN_CELL,staurosporine,0.1396,-0.8551,Moderate response,100.55
161_T,161_T_XEN_CELL,irinotecan,60.0000,1.7782,Resistant,27.70
162_T,162_T_CELL,linifanib,17.5703,1.2448,Resistant,77.12
162_T,162_T_CELL,regorafenib,14.6938,1.1671,Resistant,85.40
162_T,162_T_CELL,oxaliplatin,14.5026,1.1614,Resistant,55.30
162_T,162_T_CELL,sunitinib,8.8065,0.9448,Resistant,98.60
162_T,162_T_CELL,vandetanib,8.3476,0.9216,Resistant,99.00
162_T,162_T_CELL,nintedanib,5.0821,0.7060,Resistant,99.25
162_T,162_T_CELL,5-FU,>60.0000,1.7782,Resistant,45.90
162_T,162_T_CELL,sorafenib,2.8027,0.4476,Minor response,55.80
162_T,162_T_CELL,BI 860585,2.2898,0.3598,Minor response,97.60
162_T,162_T_CELL,gefitinib,1.0095,0.0041,Minor response,67.20
162_T,162_T_CELL,afatinib,0.6899,-0.1612,Minor response,99.30
162_T,162_T_CELL,selumetinib,0.5505,-0.2592,Minor response,62.95
162_T,162_T_CELL,AZD8931,0.0743,-1.1290,Moderate response,56.00
162_T,162_T_CELL,staurosporine,0.0095,-2.0223,Strong response,99.47
163_T,163_T_CELL,regorafenib,15.5994,1.1931,Resistant,52.20
163_T,163_T_CELL,gefitinib,10.4693,1.0199,Resistant,96.20
163_T,163_T_CELL,afatinib,10.4267,1.0181,Resistant,95.50
163_T,163_T_CELL,linifanib,8.1854,0.9130,Resistant,71.31
163_T,163_T_CELL,vandetanib,7.5632,0.8787,Resistant,108.80
163_T,163_T_CELL,nintedanib,7.3977,0.8691,Resistant,113.59
163_T,163_T_CELL,sorafenib,3.7812,0.5776,Minor response,87.30
163_T,163_T_CELL,selumetinib,3.6241,0.5592,Minor response,69.83
163_T,163_T_CELL,5-FU,>60.0000,1.7782,Resistant,19.70
163_T,163_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,22.00
163_T,163_T_CELL,sunitinib,1.7688,0.2477,Minor response,111.70
163_T,163_T_CELL,AZD8931,0.5661,-0.2471,Minor response,64.90
163_T,163_T_CELL,staurosporine,0.0434,-1.3625,Moderate response,87.43
163_T,163_T_CELL,BI 860585,0.0343,-1.4647,Strong response,85.40
163_T,163_T_CELL,irinotecan,7.7435,0.8889,Resistant,76.50
170_T,170_T2_CELL,AZD8931,60.0000,1.7782,Resistant,55.50
170_T,170_T2_CELL,sorafenib,14.4199,1.1590,Resistant,95.20
170_T,170_T2_CELL,linifanib,11.0595,1.0437,Resistant,95.64
170_T,170_T2_CELL,regorafenib,10.9718,1.0403,Resistant,92.70
170_T,170_T2_CELL,afatinib,9.2960,0.9683,Resistant,98.60
170_T,170_T2_CELL,vandetanib,8.5132,0.9301,Resistant,99.20
170_T,170_T2_CELL,sunitinib,8.3852,0.9235,Resistant,98.10
170_T,170_T2_CELL,oxaliplatin,6.4824,0.8117,Resistant,72.70
170_T,170_T2_CELL,nintedanib,4.1909,0.6223,Minor response,98.49
170_T,170_T2_CELL,gefitinib,>60.0000,1.7782,Resistant,22.30
170_T,170_T2_CELL,selumetinib,1.4223,0.1530,Minor response,64.35
170_T,170_T2_CELL,BI 860585,0.1832,-0.7371,Moderate response,98.80
170_T,170_T2_CELL,5-FU,0.0990,-1.0044,Moderate response,52.40
170_T,170_T2_CELL,staurosporine,0.0827,-1.0825,Moderate response,99.51
190_T,190_T_CELL,nintedanib,8.6014,0.9346,Resistant,100.11
190_T,190_T_CELL,sunitinib,8.5717,0.9331,Resistant,100.20
190_T,190_T_CELL,BI 860585,4.9846,0.6976,Minor response,100.20
190_T,190_T_CELL,regorafenib,3.0833,0.4890,Minor response,100.10
190_T,190_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,34.20
190_T,190_T_CELL,linifanib,2.7093,0.4329,Minor response,99.87
190_T,190_T_CELL,sorafenib,1.1074,0.0443,Minor response,100.20
190_T,190_T_CELL,gefitinib,1.0529,0.0224,Minor response,100.00
190_T,190_T_CELL,vandetanib,0.7266,-0.1387,Minor response,100.10
190_T,190_T_CELL,5-FU,0.4457,-0.3510,Minor response,55.10
190_T,190_T_CELL,AZD8931,0.1027,-0.9884,Moderate response,99.60
190_T,190_T_CELL,afatinib,0.0789,-1.1029,Moderate response,100.20
190_T,190_T_CELL,selumetinib,0.0280,-1.5528,Strong response,99.56
190_T,190_T_CELL,staurosporine,0.0081,-2.0915,Strong response,100.03
190_T,190_T_CELL,irinotecan,9.4978,0.9776,Resistant,77.50
195_T,195_T_CELL2,BI 860585,60.0000,1.7782,Resistant,72.70
195_T,195_T_CELL2,linifanib,60.0000,1.7782,Resistant,77.13
195_T,195_T_CELL2,regorafenib,60.0000,1.7782,Resistant,57.70
195_T,195_T_CELL2,sunitinib,60.0000,1.7782,Resistant,96.00
195_T,195_T_CELL2,vandetanib,60.0000,1.7782,Resistant,90.10
195_T,195_T_CELL2,afatinib,39.4478,1.5960,Resistant,82.10
195_T,195_T_CELL2,sorafenib,10.4104,1.0175,Resistant,82.20
195_T,195_T_CELL2,5-FU,>60.0000,1.7782,Resistant,10.90
195_T,195_T_CELL2,AZD8931,>60.0000,1.7782,Resistant,41.50
195_T,195_T_CELL2,gefitinib,>60.0000,1.7782,Resistant,25.60
195_T,195_T_CELL2,nintedanib,>60.0000,1.7782,Resistant,44.93
195_T,195_T_CELL2,oxaliplatin,>60.0000,1.7782,Resistant,18.50
195_T,195_T_CELL2,selumetinib,>60.0000,1.7782,Resistant,36.60
195_T,195_T_CELL2,staurosporine,0.1643,-0.7844,Moderate response,100.77
195_T,195_T_CELL2,irinotecan,6.7846,0.8315,Resistant,59.30
209_MET2,209_MET2_CELL,sorafenib,15.4191,1.1881,Resistant,94.00
209_MET2,209_MET2_CELL,AZD8931,10.1485,1.0064,Resistant,87.20
209_MET2,209_MET2_CELL,afatinib,9.0102,0.9547,Resistant,105.20
209_MET2,209_MET2_CELL,gefitinib,8.3718,0.9228,Resistant,103.20
209_MET2,209_MET2_CELL,regorafenib,8.2094,0.9143,Resistant,99.50
209_MET2,209_MET2_CELL,sunitinib,7.4815,0.8740,Resistant,104.60
209_MET2,209_MET2_CELL,vandetanib,5.6718,0.7537,Resistant,104.70
209_MET2,209_MET2_CELL,linifanib,4.9979,0.6988,Minor response,78.64
209_MET2,209_MET2_CELL,nintedanib,4.8855,0.6889,Minor response,102.87
209_MET2,209_MET2_CELL,BI 860585,2.9255,0.4662,Minor response,99.50
209_MET2,209_MET2_CELL,oxaliplatin,>60.0000,1.7782,Resistant,33.50
209_MET2,209_MET2_CELL,selumetinib,1.4931,0.1741,Minor response,93.09
209_MET2,209_MET2_CELL,5-FU,0.1936,-0.7131,Moderate response,55.70
209_MET2,209_MET2_CELL,staurosporine,0.1409,-0.8511,Moderate response,99.84
209_MET2,209_T2_CELL,irinotecan,17.6040,1.2456,Resistant,67.80
216_T,216_T_CELL,sunitinib,60.0000,1.7782,Resistant,102.40
216_T,216_T_CELL,linifanib,14.1845,1.1518,Resistant,92.94
216_T,216_T_CELL,nintedanib,13.2634,1.1227,Resistant,103.70
216_T,216_T_CELL,sorafenib,12.3558,1.0919,Resistant,90.20
216_T,216_T_CELL,selumetinib,7.6282,0.8824,Resistant,68.22
216_T,216_T_CELL,vandetanib,5.0403,0.7025,Minor response,103.40
216_T,216_T_CELL,regorafenib,3.2320,0.5095,Minor response,67.20
216_T,216_T_CELL,AZD8931,2.6128,0.4171,Minor response,74.10
216_T,216_T_CELL,gefitinib,>60.0000,1.7782,Resistant,48.70
216_T,216_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,37.40
216_T,216_T_CELL,BI 860585,1.3928,0.1439,Minor response,87.70
216_T,216_T_CELL,afatinib,0.7430,-0.1290,Minor response,104.30
216_T,216_T_CELL,5-FU,0.7139,-0.1464,Minor response,63.60
216_T,216_T_CELL,staurosporine,0.0868,-1.0615,Moderate response,101.77
227_T,227_T_CELL,sorafenib,6.1062,0.7858,Resistant,113.20
227_T,227_T_CELL,nintedanib,5.2860,0.7231,Resistant,112.21
227_T,227_T_CELL,linifanib,5.1078,0.7082,Resistant,113.26
227_T,227_T_CELL,regorafenib,3.0555,0.4851,Minor response,107.30
227_T,227_T_CELL,sunitinib,2.9224,0.4657,Minor response,113.80
227_T,227_T_CELL,5-FU,>60.0000,1.7782,Resistant,45.90
227_T,227_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,34.60
227_T,227_T_CELL,gefitinib,1.4620,0.1649,Minor response,86.00
227_T,227_T_CELL,afatinib,1.1028,0.0425,Minor response,113.80
227_T,227_T_CELL,vandetanib,0.5831,-0.2343,Minor response,66.90
227_T,227_T_CELL,BI 860585,0.3283,-0.4837,Moderate response,112.30
227_T,227_T_CELL,selumetinib,0.2272,-0.6436,Moderate response,104.46
227_T,227_T_CELL,AZD8931,0.1280,-0.8928,Moderate response,96.90
227_T,227_T_CELL,staurosporine,0.0104,-1.9830,Strong response,100.24
227_T,227_T_CELL,irinotecan,4.1908,0.6223,Minor response,97.10
234_T,234_T_CELL,gefitinib,29.1772,1.4650,Resistant,98.30
234_T,234_T_CELL,linifanib,26.1921,1.4182,Resistant,98.47
234_T,234_T_CELL,sunitinib,25.8534,1.4125,Resistant,98.50
234_T,234_T_CELL,selumetinib,22.5891,1.3539,Resistant,98.95
234_T,234_T_CELL,vandetanib,18.7665,1.2734,Resistant,98.90
234_T,234_T_CELL,nintedanib,9.0884,0.9585,Resistant,98.17
234_T,234_T_CELL,afatinib,6.9582,0.8425,Resistant,60.90
234_T,234_T_CELL,5-FU,>60.0000,1.7782,Resistant,35.00
234_T,234_T_CELL,AZD8931,>60.0000,1.7782,Resistant,17.60
234_T,234_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,48.70
234_T,234_T_CELL,sorafenib,0.9618,-0.0169,Minor response,53.80
234_T,234_T_CELL,regorafenib,0.5787,-0.2375,Minor response,57.30
234_T,234_T_CELL,BI 860585,0.1998,-0.6993,Moderate response,62.20
234_T,234_T_CELL,staurosporine,0.1298,-0.8867,Moderate response,93.80
234_T,234_T_CELL,irinotecan,28.0514,1.4480,Resistant,98.40
238_T,238_T_CELL,AZD8931,60.0000,1.7782,Resistant,75.70
238_T,238_T_CELL,sunitinib,35.6152,1.5516,Resistant,97.40
238_T,238_T_CELL,nintedanib,26.0984,1.4166,Resistant,97.83
238_T,238_T_CELL,vandetanib,23.8361,1.3772,Resistant,97.20
238_T,238_T_CELL,sorafenib,14.1427,1.1505,Resistant,98.50
238_T,238_T_CELL,linifanib,12.3578,1.0919,Resistant,98.02
238_T,238_T_CELL,afatinib,10.7650,1.0320,Resistant,98.90
238_T,238_T_CELL,regorafenib,9.4151,0.9738,Resistant,97.50
238_T,238_T_CELL,BI 860585,7.6689,0.8847,Resistant,98.50
238_T,238_T_CELL,gefitinib,>60.0000,1.7782,Resistant,26.90
238_T,238_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,21.70
238_T,238_T_CELL,selumetinib,0.6802,-0.1674,Minor response,55.95
238_T,238_T_CELL,5-FU,0.5549,-0.2558,Minor response,52.80
238_T,238_T_CELL,staurosporine,0.0865,-1.0630,Moderate response,99.15
239_T,239_T_CELL,AZD8931,60.0000,1.7782,Resistant,56.40
239_T,239_T_CELL,vandetanib,60.0000,1.7782,Resistant,98.60
239_T,239_T_CELL,sunitinib,26.4841,1.4230,Resistant,98.40
239_T,239_T_CELL,sorafenib,17.4098,1.2408,Resistant,98.50
239_T,239_T_CELL,linifanib,15.2179,1.1824,Resistant,98.40
239_T,239_T_CELL,afatinib,12.0476,1.0809,Resistant,98.90
239_T,239_T_CELL,BI 860585,11.3511,1.0550,Resistant,98.50
239_T,239_T_CELL,nintedanib,8.3170,0.9200,Resistant,98.54
239_T,239_T_CELL,regorafenib,7.4269,0.8708,Resistant,98.80
239_T,239_T_CELL,5-FU,>60.0000,1.7782,Resistant,39.30
239_T,239_T_CELL,gefitinib,>60.0000,1.7782,Resistant,41.10
239_T,239_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,31.90
239_T,239_T_CELL,selumetinib,0.3602,-0.4435,Moderate response,57.36
239_T,239_T_CELL,staurosporine,0.0758,-1.1203,Moderate response,99.34
250_T,250_T_CELL,sorafenib,5.5453,0.7439,Resistant,98.50
250_T,250_T_CELL,regorafenib,3.4013,0.5316,Minor response,83.00
250_T,250_T_CELL,afatinib,2.9926,0.4760,Minor response,101.70
250_T,250_T_CELL,BI 860585,2.3584,0.3726,Minor response,97.70
250_T,250_T_CELL,nintedanib,2.1626,0.3350,Minor response,98.41
250_T,250_T_CELL,linifanib,1.9116,0.2814,Minor response,99.40
250_T,250_T_CELL,AZD8931,1.6239,0.2106,Minor response,96.10
250_T,250_T_CELL,selumetinib,1.2691,0.1035,Minor response,91.40
250_T,250_T_CELL,5-FU,>60.0000,1.7782,Resistant,38.50
250_T,250_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,-1.30
250_T,250_T_CELL,sunitinib,0.7198,-0.1428,Minor response,101.50
250_T,250_T_CELL,gefitinib,0.6002,-0.2217,Minor response,96.90
250_T,250_T_CELL,vandetanib,0.4437,-0.3529,Minor response,100.70
250_T,250_T_CELL,staurosporine,0.0243,-1.6147,Strong response,98.80
261_T,261_T_CELL,sorafenib,60.0000,1.7782,Resistant,99.60
261_T,261_T_CELL,5-FU,21.6715,1.3359,Resistant,75.70
261_T,261_T_CELL,gefitinib,15.2659,1.1837,Resistant,99.70
261_T,261_T_CELL,AZD8931,10.4135,1.0176,Resistant,61.50
261_T,261_T_CELL,linifanib,9.9140,0.9962,Resistant,96.06
261_T,261_T_CELL,vandetanib,7.6346,0.8828,Resistant,99.90
261_T,261_T_CELL,nintedanib,7.5500,0.8779,Resistant,99.75
261_T,261_T_CELL,BI 860585,6.3604,0.8035,Resistant,99.60
261_T,261_T_CELL,afatinib,4.5457,0.6576,Minor response,99.80
261_T,261_T_CELL,regorafenib,2.4192,0.3837,Minor response,99.10
261_T,261_T_CELL,sunitinib,1.4017,0.1467,Minor response,99.70
261_T,261_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,8.90
261_T,261_T_CELL,selumetinib,0.1102,-0.9578,Moderate response,98.77
261_T,261_T_CELL,staurosporine,0.0133,-1.8761,Strong response,99.93
261_T,261_T_CELL,irinotecan,3.9849,0.6004,Minor response,82.00
276_T,276_T_CELL,oxaliplatin,50.1041,1.6999,Resistant,55.40
276_T,276_T_CELL,sorafenib,11.7125,1.0687,Resistant,77.90
276_T,276_T_CELL,regorafenib,9.7236,0.9878,Resistant,68.10
276_T,276_T_CELL,linifanib,3.1888,0.5036,Minor response,61.28
276_T,276_T_CELL,sunitinib,1.8645,0.2706,Minor response,107.20
276_T,276_T_CELL,BI 860585,1.4567,0.1634,Minor response,93.30
276_T,276_T_CELL,AZD8931,1.1937,0.0769,Minor response,89.00
276_T,276_T_CELL,afatinib,0.9902,-0.0043,Minor response,104.50
276_T,276_T_CELL,5-FU,>60.0000,1.7782,Resistant,37.30
276_T,276_T_CELL,selumetinib,0.7954,-0.0994,Minor response,84.04
276_T,276_T_CELL,vandetanib,0.6092,-0.2152,Minor response,101.10
276_T,276_T_CELL,nintedanib,0.5805,-0.2362,Minor response,104.82
276_T,276_T_CELL,gefitinib,0.3595,-0.4443,Moderate response,102.70
276_T,276_T_CELL,staurosporine,0.0623,-1.2052,Moderate response,94.11
276_T,276_T_CELL,irinotecan,4.7868,0.6800,Minor response,75.30
278_T,278_T_CELL,AZD8931,60.0000,1.7782,Resistant,77.40
278_T,278_T_CELL,nintedanib,13.1786,1.1199,Resistant,92.72
278_T,278_T_CELL,linifanib,11.7868,1.0714,Resistant,98.94
278_T,278_T_CELL,sorafenib,10.3797,1.0162,Resistant,99.70
278_T,278_T_CELL,vandetanib,9.2665,0.9669,Resistant,100.00
278_T,278_T_CELL,sunitinib,8.4355,0.9261,Resistant,100.00
278_T,278_T_CELL,regorafenib,5.7840,0.7622,Resistant,100.00
278_T,278_T_CELL,afatinib,5.6523,0.7522,Resistant,100.00
278_T,278_T_CELL,5-FU,>60.0000,1.7782,Resistant,40.90
278_T,278_T_CELL,gefitinib,>60.0000,1.7782,Resistant,32.10
278_T,278_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,-10.60
278_T,278_T_CELL,selumetinib,>60.0000,1.7782,Resistant,47.02
278_T,278_T_CELL,BI 860585,0.1931,-0.7142,Moderate response,75.60
278_T,278_T_CELL,staurosporine,0.0284,-1.5467,Strong response,99.99
281_T,281_T_CELL,AZD8931,15.5799,1.1926,Resistant,65.50
281_T,281_T_CELL,linifanib,13.6218,1.1342,Resistant,90.94
281_T,281_T_CELL,sorafenib,12.3821,1.0928,Resistant,84.80
281_T,281_T_CELL,regorafenib,8.5547,0.9322,Resistant,95.70
281_T,281_T_CELL,sunitinib,8.4557,0.9271,Resistant,100.70
281_T,281_T_CELL,nintedanib,7.9990,0.9030,Resistant,89.91
281_T,281_T_CELL,afatinib,6.0040,0.7784,Resistant,100.50
281_T,281_T_CELL,vandetanib,4.5222,0.6553,Minor response,100.50
281_T,281_T_CELL,selumetinib,4.0334,0.6057,Minor response,93.25
281_T,281_T_CELL,5-FU,3.5530,0.5506,Minor response,62.50
281_T,281_T_CELL,gefitinib,0.9569,-0.0191,Minor response,53.60
281_T,281_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,-13.10
281_T,281_T_CELL,BI 860585,0.1087,-0.9638,Moderate response,99.40
281_T,281_T_CELL,staurosporine,0.0319,-1.4962,Strong response,100.04
288_MET,288_MET_CELL,sorafenib,31.4168,1.4972,Resistant,84.30
288_MET,288_MET_CELL,linifanib,26.1197,1.4170,Resistant,85.91
288_MET,288_MET_CELL,regorafenib,20.8124,1.3183,Resistant,62.20
288_MET,288_MET_CELL,gefitinib,15.7062,1.1961,Resistant,96.70
288_MET,288_MET_CELL,AZD8931,11.7689,1.0707,Resistant,72.20
288_MET,288_MET_CELL,vandetanib,11.2657,1.0518,Resistant,102.90
288_MET,288_MET_CELL,afatinib,9.8469,0.9933,Resistant,105.60
288_MET,288_MET_CELL,sunitinib,8.2227,0.9150,Resistant,105.60
288_MET,288_MET_CELL,nintedanib,7.5895,0.8802,Resistant,99.80
288_MET,288_MET_CELL,5-FU,2.4250,0.3847,Minor response,58.50
288_MET,288_MET_CELL,oxaliplatin,>60.0000,1.7782,Resistant,7.30
288_MET,288_MET_CELL,BI 860585,0.1431,-0.8444,Moderate response,66.10
288_MET,288_MET_CELL,selumetinib,0.0479,-1.3197,Moderate response,74.79
288_MET,288_MET_CELL,staurosporine,0.0149,-1.8268,Strong response,102.10
288_MET,288_MET_CELL,irinotecan,23.8755,1.3780,Resistant,77.50
292_MET,292_MET_CELL,gefitinib,60.0000,1.7782,Resistant,103.80
292_MET,292_MET_CELL,selumetinib,18.0741,1.2571,Resistant,81.19
292_MET,292_MET_CELL,regorafenib,15.9985,1.2041,Resistant,90.90
292_MET,292_MET_CELL,AZD8931,15.6690,1.1950,Resistant,94.80
292_MET,292_MET_CELL,sorafenib,13.5044,1.1305,Resistant,103.60
292_MET,292_MET_CELL,sunitinib,9.5643,0.9807,Resistant,106.10
292_MET,292_MET_CELL,linifanib,9.3995,0.9731,Resistant,102.43
292_MET,292_MET_CELL,nintedanib,7.9741,0.9017,Resistant,102.17
292_MET,292_MET_CELL,afatinib,5.2455,0.7198,Resistant,76.00
292_MET,292_MET_CELL,vandetanib,2.6493,0.4231,Minor response,105.50
292_MET,292_MET_CELL,BI 860585,2.3138,0.3643,Minor response,104.40
292_MET,292_MET_CELL,5-FU,>60.0000,1.7782,Resistant,32.10
292_MET,292_MET_CELL,oxaliplatin,>60.0000,1.7782,Resistant,19.60
292_MET,292_MET_CELL,staurosporine,0.0020,-2.6990,Strong response,104.19
292_MET,292_MET_CELL,irinotecan,44.3364,1.6468,Resistant,57.10
299_T1,299_T1_CELL,sorafenib,20.5081,1.3119,Resistant,99.60
299_T1,299_T1_CELL,linifanib,13.5232,1.1311,Resistant,92.87
299_T1,299_T1_CELL,regorafenib,10.6571,1.0276,Resistant,97.80
299_T1,299_T1_CELL,oxaliplatin,9.4085,0.9735,Resistant,56.60
299_T1,299_T1_CELL,nintedanib,7.1378,0.8536,Resistant,98.75
299_T1,299_T1_CELL,sunitinib,6.4517,0.8097,Resistant,100.00
299_T1,299_T1_CELL,selumetinib,5.1540,0.7121,Resistant,94.10
299_T1,299_T1_CELL,5-FU,2.0789,0.3178,Minor response,61.60
299_T1,299_T1_CELL,vandetanib,1.9130,0.2817,Minor response,100.00
299_T1,299_T1_CELL,BI 860585,0.7704,-0.1133,Minor response,99.60
299_T1,299_T1_CELL,gefitinib,0.6678,-0.1754,Minor response,99.90
299_T1,299_T1_CELL,AZD8931,0.1516,-0.8193,Moderate response,97.70
299_T1,299_T1_CELL,afatinib,0.0795,-1.0996,Moderate response,100.00
299_T1,299_T1_CELL,staurosporine,0.0195,-1.7100,Strong response,99.96
299_T1,299_T1_CELL,irinotecan,9.2268,0.9651,Resistant,74.50
300_T,300_T_CELL,selumetinib,16.7201,1.2232,Resistant,98.97
300_T,300_T_CELL,AZD8931,14.9039,1.1733,Resistant,99.90
300_T,300_T_CELL,gefitinib,11.8565,1.0740,Resistant,101.10
300_T,300_T_CELL,vandetanib,9.3525,0.9709,Resistant,101.50
300_T,300_T_CELL,linifanib,8.5322,0.9311,Resistant,100.10
300_T,300_T_CELL,nintedanib,7.9518,0.9005,Resistant,101.30
300_T,300_T_CELL,sunitinib,7.5594,0.8785,Resistant,101.80
300_T,300_T_CELL,afatinib,6.3045,0.7997,Resistant,101.80
300_T,300_T_CELL,regorafenib,5.3042,0.7246,Resistant,98.50
300_T,300_T_CELL,sorafenib,4.3084,0.6343,Minor response,101.90
300_T,300_T_CELL,BI 860585,1.2601,0.1004,Minor response,101.70
300_T,300_T_CELL,5-FU,>60.0000,1.7782,Resistant,23.90
300_T,300_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,41.30
300_T,300_T_CELL,staurosporine,0.0901,-1.0453,Moderate response,100.49
300_T,300_T_CELL,irinotecan,10.5853,1.0247,Resistant,88.00
302_MET,302_MET_CELL,gefitinib,60.0000,1.7782,Resistant,99.50
302_MET,302_MET_CELL,sorafenib,60.0000,1.7782,Resistant,99.10
302_MET,302_MET_CELL,nintedanib,24.1781,1.3834,Resistant,99.79
302_MET,302_MET_CELL,linifanib,20.0000,1.3010,Resistant,92.76
302_MET,302_MET_CELL,afatinib,15.3661,1.1866,Resistant,99.90
302_MET,302_MET_CELL,BI 860585,12.3045,1.0901,Resistant,92.00
302_MET,302_MET_CELL,regorafenib,11.9193,1.0763,Resistant,98.60
302_MET,302_MET_CELL,sunitinib,8.0256,0.9045,Resistant,99.70
302_MET,302_MET_CELL,vandetanib,0.1986,-0.7020,Moderate response,56.10
302_MET,302_MET_CELL,5-FU,>60.0000,1.7782,Resistant,19.70
302_MET,302_MET_CELL,AZD8931,>60.0000,1.7782,Resistant,37.30
302_MET,302_MET_CELL,oxaliplatin,>60.0000,1.7782,Resistant,19.10
302_MET,302_MET_CELL,staurosporine,0.0790,-1.1024,Moderate response,100.02
302_MET,302_MET_CELL,selumetinib,0.0604,-1.2190,Moderate response,75.56
302_MET,302_MET_CELL,irinotecan,29.8935,1.4756,Resistant,66.60
315_MET,315_MET_CELL,gefitinib,60.0000,1.7782,Resistant,101.80
315_MET,315_MET_CELL,selumetinib,28.2495,1.4510,Resistant,86.24
315_MET,315_MET_CELL,sorafenib,11.5169,1.0613,Resistant,96.20
315_MET,315_MET_CELL,vandetanib,10.9707,1.0402,Resistant,101.40
315_MET,315_MET_CELL,afatinib,10.8866,1.0369,Resistant,103.10
315_MET,315_MET_CELL,linifanib,8.7756,0.9433,Resistant,85.26
315_MET,315_MET_CELL,sunitinib,7.4168,0.8702,Resistant,103.10
315_MET,315_MET_CELL,regorafenib,6.5026,0.8131,Resistant,91.10
315_MET,315_MET_CELL,nintedanib,2.0735,0.3167,Minor response,103.00
315_MET,315_MET_CELL,5-FU,2.0082,0.3028,Minor response,53.20
315_MET,315_MET_CELL,BI 860585,1.5264,0.1837,Minor response,101.80
315_MET,315_MET_CELL,AZD8931,>60.0000,1.7782,Resistant,43.50
315_MET,315_MET_CELL,oxaliplatin,>60.0000,1.7782,Resistant,-12.60
315_MET,315_MET_CELL,staurosporine,0.0025,-2.6021,Strong response,100.52
326_T,326_T_CELL,sorafenib,17.0930,1.2328,Resistant,101.90
326_T,326_T_CELL,sunitinib,6.7913,0.8320,Resistant,102.00
326_T,326_T_CELL,regorafenib,5.7213,0.7575,Resistant,100.50
326_T,326_T_CELL,BI 860585,4.3265,0.6361,Minor response,100.10
326_T,326_T_CELL,nintedanib,3.3659,0.5271,Minor response,99.67
326_T,326_T_CELL,linifanib,2.9706,0.4728,Minor response,89.12
326_T,326_T_CELL,vandetanib,0.7267,-0.1386,Minor response,102.00
326_T,326_T_CELL,selumetinib,0.2431,-0.6142,Moderate response,96.10
326_T,326_T_CELL,AZD8931,0.2116,-0.6745,Moderate response,98.90
326_T,326_T_CELL,afatinib,0.1927,-0.7151,Moderate response,102.10
326_T,326_T_CELL,gefitinib,0.1219,-0.9140,Moderate response,101.60
326_T,326_T_CELL,5-FU,>60.0000,1.7782,Resistant,46.80
326_T,326_T_CELL,oxaliplatin,>60.0000,1.7782,Resistant,-0.50
326_T,326_T_CELL,staurosporine,0.0160,-1.7959,Strong response,99.59
326_T,326_T_CELL,irinotecan,6.1808,0.7910,Resistant,82.40
327_T,327_T_CELL,sorafenib,7.2008,0.8574,Resistant,99.70
327_T,327_T_CELL,linifanib,5.2697,0.7218,Resistant,99.77
327_T,327_T_CELL,regorafenib,4.8145,0.6826,Minor response,100.00
327_T,327_T_CELL,nintedanib,3.2472,0.5115,Minor response,99.84
327_T,327_T_CELL,5-FU,2.8226,0.4506,Minor response,83.50
327_T,327_T_CELL,vandetanib,2.1643,0.3353,Minor response,99.90
327_T,327_T_CELL,sunitinib,1.6861,0.2269,Minor response,99.70
327_T,327_T_CELL,oxaliplatin,1.4631,0.1653,Minor response,85.70
327_T,327_T_CELL,gefitinib,0.4801,-0.3187,Minor response,99.60
327_T,327_T_CELL,BI 860585,0.3181,-0.4974,Moderate response,99.90
327_T,327_T_CELL,selumetinib,0.1515,-0.8196,Moderate response,99.75
327_T,327_T_CELL,AZD8931,0.0428,-1.3686,Moderate response,99.70
327_T,327_T_CELL,afatinib,0.0074,-2.1308,Strong response,100.00
327_T,327_T_CELL,staurosporine,0.0007,-3.1549,Strong response,99.96
327_T,327_T_CELL,irinotecan,1.8114,0.2580,Minor response,91.90
330_T,330_T_CELL,regorafenib,23.9985,1.3802,Resistant,92.40
330_T,330_T_CELL,linifanib,17.5952,1.2454,Resistant,93.51
330_T,330_T_CELL,sorafenib,14.7063,1.1675,Resistant,105.60
330_T,330_T_CELL,sunitinib,9.0341,0.9559,Resistant,108.40
330_T,330_T_CELL,nintedanib,5.9894,0.7774,Resistant,108.18
330_T,330_T_CELL,vandetanib,2.8352,0.4526,Minor response,105.70
330_T,330_T_CELL,gefitinib,2.0101,0.3032,Minor response,103.60
330_T,330_T_CELL,5-FU,0.5057,-0.2961,Minor response,59.00
330_T,330_T_CELL,selumetinib,0.3520,-0.4535,Moderate response,97.51
330_T,330_T_CELL,oxaliplatin,0.1935,-0.7133,Moderate response,55.90
330_T,330_T_CELL,BI 860585,0.1915,-0.7178,Moderate response,104.50
330_T,330_T_CELL,AZD8931,0.1153,-0.9382,Moderate response,95.40
330_T,330_T_CELL,afatinib,0.0386,-1.4134,Moderate response,108.00
330_T,330_T_CELL,staurosporine,0.0222,-1.6536,Strong response,101.68
330_T,330_T_CELL,irinotecan,2.1361,0.3296,Minor response,69.30
352_MET,352_MET_CELL,gefitinib,8.9871,0.9536,Resistant,100.60
352_MET,352_MET_CELL,sorafenib,6.2573,0.7964,Resistant,100.40
352_MET,352_MET_CELL,linifanib,5.9985,0.7780,Resistant,100.12
352_MET,352_MET_CELL,regorafenib,5.6538,0.7523,Resistant,97.70
352_MET,352_MET_CELL,AZD8931,3.7490,0.5739,Minor response,100.60
352_MET,352_MET_CELL,afatinib,3.1251,0.4949,Minor response,101.10
352_MET,352_MET_CELL,vandetanib,2.9300,0.4669,Minor response,101.10
352_MET,352_MET_CELL,sunitinib,2.5959,0.4143,Minor response,101.10
352_MET,352_MET_CELL,nintedanib,2.0213,0.3056,Minor response,100.90
352_MET,352_MET_CELL,5-FU,1.8544,0.2682,Minor response,64.40
352_MET,352_MET_CELL,selumetinib,0.9643,-0.0158,Minor response,100.22
352_MET,352_MET_CELL,BI 860585,0.7192,-0.1432,Minor response,101.10
352_MET,352_MET_CELL,oxaliplatin,>60.0000,1.7782,Resistant,20.50
352_MET,352_MET_CELL,staurosporine,0.0080,-2.0969,Strong response,100.54
352_MET,352_MET_CELL,irinotecan,21.4537,1.3315,Resistant,81.50
364_MET,364_MET_CELL,oxaliplatin,33.2990,1.5224,Resistant,65.70
364_MET,364_MET_CELL,linifanib,27.0050,1.4314,Resistant,93.45
364_MET,364_MET_CELL,regorafenib,14.8816,1.1726,Resistant,98.00
364_MET,364_MET_CELL,sorafenib,14.1781,1.1516,Resistant,99.60
364_MET,364_MET_CELL,sunitinib,7.6416,0.8832,Resistant,100.00
364_MET,364_MET_CELL,nintedanib,7.2231,0.8587,Resistant,100.05
364_MET,364_MET_CELL,AZD8931,6.5080,0.8134,Resistant,88.30
364_MET,364_MET_CELL,vandetanib,5.5518,0.7444,Resistant,100.10
364_MET,364_MET_CELL,gefitinib,4.7125,0.6733,Minor response,99.80
364_MET,364_MET_CELL,selumetinib,1.8302,0.2625,Minor response,86.63
364_MET,364_MET_CELL,BI 860585,0.5730,-0.2418,Minor response,99.10
364_MET,364_MET_CELL,afatinib,0.3685,-0.4336,Moderate response,100.10
364_MET,364_MET_CELL,5-FU,>60.0000,1.7782,Resistant,35.10
364_MET,364_MET_CELL,staurosporine,0.0593,-1.2269,Moderate response,100.14
364_MET,364_MET_CELL,irinotecan,40.6065,1.6086,Resistant,63.80